Harbour BioMed and Sinopharm form a biologics R&D consortium spanning antibody discovery, clinical development, manufacturing and commercialisation.
Read how Harbour BioMed’s Amgen patent win could reshape antibody discovery licensing, biologics IP and biotech investor sentiment.
Harbour BioMed has signed a global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multispecific antibodies. The deal could be worth over $1.1 billion across upfront payments, milestones, and royalties. It also signals growing interest in platforms capable of generating novel immunotherapies for complex diseases. The announcement is not